| 88863-6 |
Lung cancer antibody panel |
- |
Ser/Plas |
Pt |
- |
IA |
|
ACTIVE |
Lung cancer antibody panel - Serum or Plasma by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
|
|
EarlyCDT�® is a registered trademark of Oncimmune. Used with permission. |
|
|
|
|
PANEL.SERO |
|
88863-6 |
|
IA |
|
|
Order |
|
|
|
0 |
Lung cancer antibody panel SerPl IA |
|
|
|
|
|
Ab; EarlyCDT; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Lung cancer Ab; MEIA; Pan; PANEL.SEROLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.64 |
2.64 |
|
Panel |
|
|
EarlyCDT�® is a registered trademark of Oncimmune. Used with permission. |
|
|
|
|
|
|
0 |
| 88864-4 |
Microbiology CNAMTS panel |
- |
Cornea/Conjunctiva |
Pt |
- |
|
|
ACTIVE |
Microbiology CNAMTS panel - Cornea or Conjunctiva |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
88864-4 |
|
|
|
|
Order |
|
|
|
0 |
Micro CNAMTS panel Corn/Cnjt |
|
|
|
|
|
Corn/Cnjt; Corneal; Micro CNAMTS panel; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random |
2.64 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 88865-1 |
Chemical XXX |
Prid |
XXX |
Pt |
Nom |
|
|
ACTIVE |
Other Chemical [Identifier] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
88865-1 |
|
|
|
|
Observation |
|
|
|
0 |
Other Chemical Spec |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Identity or presence; Misc; Miscellaneous; Nominal; Other; Other Chemical; Point in time; Random; Spec; To be specified in another part of the message; Unspecified; Vet; Veterinary |
2.69 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88866-9 |
Chemical XXX |
MCnt |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Other Chemical [Mass/mass] in Specimen |
|
MIN |
DefinitionDescription |
|
|
mg/kg |
|
|
|
|
|
|
DRUG/TOX |
|
88866-9 |
|
|
|
|
Both |
|
|
|
0 |
Other Chemical Spec-mCnt |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Mass content; Misc; Miscellaneous; Other; Other Chemical; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified; Vet; Veterinary |
2.69 |
2.64 |
|
|
|
|
|
|
|
mg/kg |
|
|
|
0 |
| 88867-7 |
Chemical XXX |
MCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Other Chemical [Mass/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
g/dL |
|
|
|
|
|
|
DRUG/TOX |
|
88867-7 |
|
|
|
|
Observation |
|
|
|
0 |
Other Chemical Spec-mCnc |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Other Chemical; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified; Vet; Veterinary |
2.69 |
2.64 |
|
|
|
|
|
|
|
g/dL |
|
|
|
0 |
| 88868-5 |
Veterinary toxicology panel |
- |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Veterinary toxicology quantitative panel - Unspecified specimen |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
88868-5 |
|
|
|
|
Order |
|
|
|
0 |
Vet toxic pnl XXX Qn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Other; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Toxicology Pnl; Unspecified; Vet; Vet toxic pnl; Veterinary |
2.69 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 88869-3 |
Veterinary toxicology panel |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
Veterinary toxicology panel [Presence] - Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
88869-3 |
|
|
|
|
Order |
|
|
|
0 |
Vet toxic pnl Spec Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Ordinal; Other; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pnl; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Toxicology Pnl; Unspecified; Vet; Vet toxic pnl; Veterinary |
2.69 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 8887-2 |
Class |
Type |
Heart rate device |
Pt |
Nom |
|
|
ACTIVE |
Type of Heart rate device |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DEVICES |
|
8887-2 |
|
|
|
|
|
|
|
|
0 |
Hrt Rate Device Class |
|
|
|
|
|
Cardiac; Cardio; Cardiology; Heart beat; Heart Disease; Hrt; Hrt Rate Device; Nominal; Point in time; Pulse; Pulse device; Random; Typ |
2.27 |
1.0h(3) |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88870-1 |
Drug regimen review identified potential medication issues in the last 3D |
Find |
^Patient |
3D |
Ord |
CMS Assessment |
|
ACTIVE |
Drug regimen review identified potential medication issues in the last 3 days [CMS Assessment] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CMS |
|
88870-1 |
|
CMS Assessment |
|
|
Observation |
|
|
|
0 |
|
|
|
|
|
|
3 days; Centers for Medicare and Medicaid Assessment; Drugs; Finding; Findings; Ordinal; Past; QL; Qual; Qualitative; Screen; Survey |
2.67 |
2.64 |
|
|
|
|
|
|
|
|
|
|
Release 2.67: ANSWER_LIST_TYPE: Changed Answer List Type from Normative to Example to accommodate Override Answer Lists |
0 |
| 88871-9 |
Medication follow-up in the last 3D |
Find |
^Patient |
3D |
Ord |
CMS Assessment |
|
ACTIVE |
Medication follow-up in the last 3 days [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.CMS |
|
88871-9 |
|
CMS Assessment |
|
|
Observation |
|
|
|
0 |
|
|
|
|
|
|
3 days; Centers for Medicare and Medicaid Assessment; Finding; Findings; Ordinal; Past; QL; Qual; Qualitative; Screen; Survey |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88872-7 |
IRF-PAI v2.0 - Medications - admission |
- |
^Patient |
3D |
- |
CMS Assessment |
|
ACTIVE |
IRF-PAI v2.0 - Medications - admission [CMS Assessment] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88872-7 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
|
|
3 days; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Survey |
2.69 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.69: COMPONENT: Updated to state the most recent version of IRF-PAI that uses this panel.; TIME_ASPCT: Corrected to align with the Timing for the child terms in this panel.; Release 2.67: COMPONENT: Assessment version added to Component to distinguish this panel from similar panels in other versions of the assessment. |
0 |
| 88873-5 |
Sympathomimetics |
PrThr |
Ser/Plas/Bld |
Pt |
Ord |
Confirm |
|
ACTIVE |
Sympathomimetics [Presence] in Serum, Plasma or Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
88873-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Sympathomimetics SerPlBld Ql Cfm |
|
|
|
|
|
Amphetamine; Benzedrine; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Ephedrine; GCMS; LC/MS/MS; Mescaline; Ordinal; Pl; PlasBld; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.73 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88874-3 |
Mycobacterium tuberculosis complex DNA |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
TRIAL |
Mycobacterium tuberculosis complex DNA [Presence] in Isolate or Specimen by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88874-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
M TB Cmplx DNA Islt/Spm Ql |
|
|
|
|
|
Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Compx; Deoxyribonucleic acid; ID; Infectious Disease; InfectiousDisease; Islt; Islt/Spm; Isol; M tb; M TB Cmplx; M tuberculosis; Microbiology; Molecular genetics; Mtb; MTBC; Myco; Mycobact; Mycobacterium tuberculosum; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; TB; Tuberculosis |
2.73 |
2.64 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 88875-0 |
Measles virus genotype A vaccine strain N gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Measles virus genotype A vaccine strain N gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
88875-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
MeVA vac str N gene Spec Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; MeV; MeVA vac str N gene; Misc; Miscellaneous; Molecular pathology; MOLPATH; Msls; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Rubeola; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88876-8 |
Measles virus genotype A vaccine strain N gene |
ThreshNum |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Measles virus genotype A vaccine strain N gene [Cycle Threshold #] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MOLPATH |
|
88876-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
MeVA vac str N gene Ct Spec Qn NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; MeV; MeVA vac str N gene; Misc; Miscellaneous; Molecular pathology; MOLPATH; Msls; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Rubeola; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.64 |
|
|
|
|
|
|
|
{Ct_value} |
|
|
|
0 |
| 88877-6 |
Date vaccination indication effective |
Date |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Date vaccination indication effective |
|
ADD |
DefinitionDescription |
|
|
MMDDYY |
|
|
|
|
|
|
VACCIN |
|
88877-6 |
|
|
|
|
Observation |
|
|
|
0 |
Date vaccine ind effective |
|
|
|
|
|
Date vaccine ind effective; Immunizations; Point in time; QNT; Quan; Quant; Quantitative; Random; Vaccine |
2.64 |
2.64 |
|
|
|
|
|
|
|
{mm/dd/yyyy} |
|
|
|
0 |
| 88878-4 |
Date of condition abatement |
Date |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Date of condition abatement |
|
ADD |
DefinitionDescription |
|
|
MMDDYY |
|
|
|
|
|
|
H&P.HX |
|
88878-4 |
|
|
|
|
Observation |
|
|
|
0 |
Date of condition abatement |
|
|
|
|
|
H+P; H+P.HX; P prime; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.64 |
2.64 |
|
|
|
|
|
|
|
{mm/dd/yyyy} |
|
|
|
0 |
| 88879-2 |
Date vaccination indication expires |
Date |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Date vaccination indication expires |
|
ADD |
DefinitionDescription |
|
|
MMDDYY |
|
|
|
|
|
|
VACCIN |
|
88879-2 |
|
|
|
|
Observation |
|
|
|
0 |
Date vaccination indication expires |
|
|
|
|
|
Immunizations; Point in time; QNT; Quan; Quant; Quantitative; Random; Vaccine |
2.64 |
2.64 |
|
|
|
|
|
|
|
{mm/dd/yyyy} |
|
|
|
0 |
| 8888-0 |
Heart rate measure duration |
Time |
Heart study |
* |
Qn |
|
|
ACTIVE |
Heart rate measure duration |
|
MIN |
DefinitionDescription |
|
|
s; min |
|
|
|
|
|
|
HRTRATE.ATOM |
|
8888-0 |
|
|
|
|
|
|
|
|
0 |
Heart rate measure duration |
|
|
|
|
|
Cardiac; Cardio; Cardiology; Durat; Envelope duration; Heart beat; Heart Disease; HEART RATE.ATOM; Hrt; Pulse; QNT; Quan; Quant; Quantitative |
2.48 |
1.0h(3) |
|
|
|
|
|
|
|
s;min |
|
|
|
0 |
| 88880-0 |
Monocyte distribution width |
EntVol |
Bld |
Pt |
Qn |
Automated |
|
ACTIVE |
Monocyte distribution width [Entitic volume] in Blood by Automated |
|
ADD |
DefinitionDescription |
|
|
fL |
|
|
|
|
|
|
HEM/BC |
|
88880-0 |
|
Automated |
|
|
Both |
|
|
|
0 |
MDW Bld Auto |
|
|
|
|
|
Auto; Automated detection; Blood; Elec; Elect; Electr; Entitic volume; HEMATOLOGY/CELL COUNTS; MDW; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
fL |
|
|
|
0 |
| 88881-8 |
Smith extractable nuclear D Ab |
PrThr |
Ser |
Pt |
Ord |
Line blot |
|
ACTIVE |
Smith extractable nuclear D Ab [Presence] in Serum by Line blot |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
88881-8 |
|
Line blot |
|
|
Both |
|
|
|
0 |
ENA SM-D Ab Ser Ql Line blot |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dextro; ENA; ENA SM; ENA SM-D; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rh; Rhesus; Screen; Serology; Serum; SM; SmD; SR |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88882-6 |
Smith extractable nuclear B Ab |
PrThr |
Ser |
Pt |
Ord |
Line blot |
|
ACTIVE |
Smith extractable nuclear B Ab [Presence] in Serum by Line blot |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
88882-6 |
|
Line blot |
|
|
Both |
|
|
|
0 |
ENA SM-B Ab Ser Ql Line blot |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ENA; ENA SM; ENA SM-B; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SM; SmB; SR |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 88883-4 |
Connective tissue autoimmune Ab panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
Connective tissue autoimmune Ab panel - Serum |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SERO |
|
88883-4 |
|
|
|
|
Order |
|
|
|
0 |
Connective tiss Ab Pnl Ser |
|
|
|
|
|
Conn tiss; Connective tiss Ab Pnl; Connective tissue Ab; Pan; PANEL.SEROLOGY; Panl; Pnl; Point in time; Random; Serology; Serum; SR |
2.68 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
Release 2.68: METHOD_TYP: Removed Method of Line blot because this panel contains children with different Methods.; COMPONENT: Updated for naming consistency across autoimmune panels. |
0 |
| 88884-2 |
Fatty acid omega-3 & omega-6 panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Fatty acid omega-3 and omega-6 panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
88884-2 |
|
|
|
|
Order |
|
|
|
0 |
FA omega-3 + omega-6 panel SerPl |
|
|
|
|
|
Acd; Acids; Chemistry; DHA; Docosahexaenoate; Docosapentaenic acid; DPA; Eicosapentaenoate; EPA; FA omega-3 + omega-6 panel; III; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.65 |
2.64 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 88885-9 |
Delafloxacin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Delafloxacin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
88885-9 |
|
|
|
|
Both |
|
|
|
0 |
DLX Susc Islt |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Baxdela; DLX; Fluoroquinolone; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.64 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
